STAT July 17, 2024
Elaine Chen

Around the world, patients suddenly can’t find enough of the insulins made by companies they have long relied on to do so.

In the U.S., Novo Nordisk’s recent decision to discontinue a product has left patients with fewer options. At the same time, patients are encountering shortages of other products from Novo and Eli Lilly. For months, pharmacies have been running out of vials of certain insulins that patients use to fill the pumps they wear on their body.

Supply issues have also spread to the U.K., where patients struggle to find not only vials, but also injectable pens of insulin.

And in South Africa, Novo, which had been supplying the government with human insulin injection pens for years, has...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article